Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
| Autor: | Itsuro Nagase, Satoshi Yoshida, Atsunori Kashiwagi, Kenichi Kazuta |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Hematocrit Placebo Gastroenterology chemistry.chemical_compound Weight loss Internal medicine Diabetes mellitus Internal Medicine medicine Sodium‐dependent glucose co‐transporter 2 Glycemic Oral antidiabetic drugs medicine.diagnostic_test business.industry Type 2 Diabetes Mellitus General Medicine Articles medicine.disease Clinical Trial Ipragliflozin Clinical Science and Care chemistry Hyperglycemia Glycated hemoglobin medicine.symptom business |
| Zdroj: | Journal of Diabetes Investigation |
| ISSN: | 2040-1116 |
| Popis: | Aims/Introduction In the present dose–response study, we evaluated the efficacy and safety of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose cotransporter 2, in Japanese patients with type 2 diabetes mellitus. Materials and Methods A total of 361 patients from 39 Japanese centers were randomized to receive either once-daily oral ipragliflozin (12.5, 25, 50 or 100 mg) or a placebo for 12 weeks. Results All ipragliflozin-treated groups had clinically significant, dose-dependent decreases in glycated hemoglobin (HbA1c) and fasting plasma glucose levels compared with placebo-treated groups. The adjusted mean difference in HbA1c change from baseline to the end of treatment between the placebo and 12.5, 25, 50, and 100 mg ipragliflozin groups were −0.61%, −0.97%, −1.29%, and −1.31%, respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text